ReviewAntiviral research2008
Molecular strategies to inhibit the replication of RNA viruses.
Review in Antiviral research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 142 citations in OpenAlex.
- Structure, Function and Inhibition of Helicases Involved in Virus Infection.Biomolecules · 2026Review
- Review
- Article
- New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells.PLoS computational biology · 2023Article
- Preclinical efficacy and safety of novel SNAT against SARS-CoV-2 using a hamster model.Drug delivery and translational research · 2022Article
- Efficient elimination of RNA mycoviruses inFrontiers in microbiology · 2022Article
- Functional and Pathological Roles of AHCY.Frontiers in cell and developmental biology · 2021Review
- Advances in developing small molecule SARS 3CLTetrahedron · 2021Review
- Inhibiting the reproduction of SARS-CoV-2 through perturbations in human lung cell metabolic network.Life science alliance · 2021Article
- Investigation of Binding Affinity between Potential Antiviral Agents and PB2 Protein of Influenza A: Non-equilibrium Molecular Dynamics Simulation Approach.International journal of medical sciences · 2020Article
- Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.Frontiers in immunology · 2019Article
- Integrated human-virus metabolic stoichiometric modelling predicts host-based antiviral targets against Chikungunya, Dengue and Zika viruses.Journal of the Royal Society, Interface · 2018Article
- Identification of tell-tale patterns in the 3' non-coding region of hantaviruses that distinguish HCPS-causing hantaviruses from HFRS-causing hantaviruses.Emerging microbes & infections · 2018Article
- Therapeutic Approaches for Zika Virus Infection of the Nervous System.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.Journal of microbiology (Seoul, Korea) · 2017Review
- Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Review
- Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT).Scientific reports · 2016Article
- Reverse Genetics Approaches to Control Arenavirus.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Development of Small-Molecule Antivirals for Ebola.Medicinal research reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are virtually no antiviral drugs available for the treatment of infections with RNA viruses. This is particularly worrisome since most of the highly pathogenic and emerging viruses are, and will likely continue to be, RNA viruses. These viruses can cause acute, severe illness, including severe respiratory disease, hemorrhagic fever and encephalitis, with a high case fatality rate. It is important to have potent and safe drugs at hand that can be used for the treatment or prophylaxis of such infections. Drugs approved for the treatment of RNA virus infections (other than HIV) are the influenza M2 channel inhibitors, amantadine and rimantadine; the influenza neuraminidase inhibitors, oseltamivir and zanamivir, and ribavirin for the treatment of infections with respiratory syncytial virus and hepatitis C virus. The molecular mechanism(s) by which ribavirin inhibits viral replication, such as depletion of intracellular GTP pools and induction of error catastrophe, may not readily allow the design of analogues that are more potent/selective than the parent drug. Highly pathogenic RNA viruses belong to a variety of virus families, each having a particular replication strategy, thus offering a wealth of potential targets to selectively inhibit viral replication. We here provide a non-exhaustive review of potential experimental strategies, using small molecules, to inhibit the replication of several RNA viruses. Other approaches, such as the use of interferon or other host-response modifiers, immune serum or neutralizing antibodies, are not addressed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.